BRPI0516531A - imunoterapia de distúrbios auto-imunes - Google Patents

imunoterapia de distúrbios auto-imunes

Info

Publication number
BRPI0516531A
BRPI0516531A BRPI0516531-8A BRPI0516531A BRPI0516531A BR PI0516531 A BRPI0516531 A BR PI0516531A BR PI0516531 A BRPI0516531 A BR PI0516531A BR PI0516531 A BRPI0516531 A BR PI0516531A
Authority
BR
Brazil
Prior art keywords
immunotherapy
autoimmune diseases
cell depleting
agents
compositions
Prior art date
Application number
BRPI0516531-8A
Other languages
English (en)
Inventor
Anand Iyer
Kyriaki Dunussi-Joannopoulos
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0516531A publication Critical patent/BRPI0516531A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

IMUNOTERAPIA DE DISTúRBIOS AUTO-IMUNES. São descritas composições e métodos para tratamento de doenças auto-imunes. Em particular, é descrito o uso de agentes de depleção de células B e conjugados de agente de depleção de células B/droga citotóxica com um carregamento de droga significativamente mais elevado do que em procedimentos anteriormente relatados e com agregação diminuida e fração conjugada baixa (LCF) no tratamento de doenças auto-imunes. São também descritas terapias de combinação e composições para tratar doenças auto-imunes, incluindo os agentes de depleção de células B, conjugados e/ou agentes anticitocina.
BRPI0516531-8A 2004-10-08 2005-10-11 imunoterapia de distúrbios auto-imunes BRPI0516531A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61664704P 2004-10-08 2004-10-08
US68600105P 2005-06-01 2005-06-01
PCT/US2005/036436 WO2006042240A2 (en) 2004-10-08 2005-10-11 Immunotherapy of autoimmune disorders

Publications (1)

Publication Number Publication Date
BRPI0516531A true BRPI0516531A (pt) 2008-09-09

Family

ID=36148997

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516531-8A BRPI0516531A (pt) 2004-10-08 2005-10-11 imunoterapia de distúrbios auto-imunes

Country Status (13)

Country Link
US (2) US20070264257A1 (pt)
EP (1) EP1796735A4 (pt)
JP (1) JP2008515926A (pt)
AR (1) AR052774A1 (pt)
AU (1) AU2005295041A1 (pt)
BR (1) BRPI0516531A (pt)
CA (1) CA2582919A1 (pt)
GT (1) GT200500283A (pt)
MX (1) MX2007004049A (pt)
PE (1) PE20060972A1 (pt)
SV (1) SV2006002258A (pt)
TW (1) TW200630106A (pt)
WO (1) WO2006042240A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
DE60335552D1 (de) 2002-09-11 2011-02-10 Genentech Inc Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
EP1776384B1 (en) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Variant fc regions
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
EP1899379B1 (en) * 2005-06-20 2018-04-11 E. R. Squibb & Sons, L.L.C. Cd19 antibodies and their uses
US7956160B2 (en) 2005-07-22 2011-06-07 Amgen Inc. Concentrated protein lyophilates, methods, and uses
SI1928503T1 (sl) 2005-08-24 2012-11-30 Immunogen Inc Postopek za pripravo konjugatov majtansinoid protitelo
WO2007140371A2 (en) * 2006-05-30 2007-12-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
JP2008105953A (ja) * 2006-10-23 2008-05-08 Kyoto Sangyo Univ Ｂ細胞傷害抑制剤
CN102558001B (zh) 2007-05-22 2015-09-23 惠氏有限责任公司 制造酰肼的改良方法
NZ581742A (en) * 2007-06-08 2012-09-28 Biogen Idec Inc Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
SG10201402815VA (en) * 2008-04-09 2014-09-26 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
NZ590330A (en) * 2008-07-21 2012-08-31 Immunomedics Inc Structural variants of anti-cd20 antibodies for improved therapeutic characteristics
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CN104984360A (zh) * 2009-06-03 2015-10-21 伊缪诺金公司 轭合方法
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
JP4495776B1 (ja) * 2009-07-30 2010-07-07 日本製薬株式会社 融合蛋白質
CN105001334A (zh) 2010-02-10 2015-10-28 伊缪诺金公司 Cd20抗体及其用途
KR102272828B1 (ko) 2011-03-29 2021-07-05 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
BR112014006822B1 (pt) * 2011-09-22 2021-05-18 Amgen Inc. Proteína de ligação ao antígeno cd27l, composição compreendendo uma proteína de ligação ao antígeno cd27l, ácido nucleico isolado, vetor de expressão, célula hospedeira recombinante procariótica, método de preparação de um conjugado de droga e anticorpo cd27l e uso de uma proteína de ligação ao antígeno cd27l
AU2013326881B2 (en) 2012-10-04 2018-08-02 Immunogen, Inc. Use of a PVDF membrane to purify cell-binding agent cytotoxic agent conjugates
US9873740B2 (en) 2013-07-16 2018-01-23 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
US20160143866A1 (en) * 2014-11-21 2016-05-26 Eli D. Ehrenpreis Combination Therapy for Administration of Monoclonal Antibodies
WO2017037707A1 (en) 2015-09-02 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
TWI811892B (zh) 2015-09-25 2023-08-11 美商建南德克公司 抗tigit抗體及使用方法
GB201610512D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
CN115054587B (zh) * 2022-05-12 2023-11-21 山东大学 一种胎盘靶向纳米药物的制备及在妊娠合并自身免疫性疾病治疗中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1194167B1 (en) * 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
WO2003072036A2 (en) * 2002-02-21 2003-09-04 Duke University Treatment methods using anti-cd22 antibodies
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
PT1572744E (pt) * 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins

Also Published As

Publication number Publication date
EP1796735A4 (en) 2007-12-12
SV2006002258A (es) 2006-09-19
US20110027273A1 (en) 2011-02-03
US20070264257A1 (en) 2007-11-15
JP2008515926A (ja) 2008-05-15
MX2007004049A (es) 2007-05-24
WO2006042240A3 (en) 2006-09-21
GT200500283A (es) 2006-05-08
AU2005295041A1 (en) 2006-04-20
WO2006042240A2 (en) 2006-04-20
EP1796735A2 (en) 2007-06-20
PE20060972A1 (es) 2006-12-03
CA2582919A1 (en) 2006-04-20
TW200630106A (en) 2006-09-01
AR052774A1 (es) 2007-04-04

Similar Documents

Publication Publication Date Title
BRPI0516531A (pt) imunoterapia de distúrbios auto-imunes
AU2018275894A1 (en) Articles of manufacture and methods for treatment using adoptive cell therapy
LUC00011I2 (pt)
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
WO2007101224A3 (en) Inhibitors of the unfolded protein response and methods for their use
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
EA200602047A1 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
BRPI0511396A (pt) derivados de retinal e métodos para uso no tratamento de enfermidades visuais
CY1107906T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
BR112013010829A2 (pt) composição farmacêutica intravenenosa para proporcionar alívio da dor e / ou da inflamação, uso e método da mesma
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
BRPI0517983A (pt) uso de corticosteróide em associação com diurético e antiácido para tratamento de estenose vascular e prevenção de reestenose vascular
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
EA202091087A1 (ru) Способы ослабления побочных эффектов терапии конъюгатом "антитело против cd30-лекарственное средство"
Loprinzi Key Symptom-Intervention Takeaways from ASCO 2014

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2212 DE 28/05/2013.